MSB 4.69% $1.45 mesoblast limited

Ann: 36-Month Results of Phase 3 Trial in Chronic Low Back Pain, page-19

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 35,472 Posts.
    lightbulb Created with Sketch. 2863
    Interesting highlighting, and I thought this was one of the most important observations for possible disc "regeneration"

    "suggesting that greatest benefits may be seen when the therapy is administered earlier in the disease process when there is active inflammation and before irreversible fibrosis of the intervertebral disc has occurred"

    going to be an expensive pain killer vs $5 per month

    and where are those MRI's - the above quote may explain the absence.

    https://regenexx.com/blog/did-the-mesoblast-stem-cell-disc-trial-succeed-or-fail/
    Last edited by Sector: 12/01/22
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.